Pirtobrutinib in Covalent Bruton Tyrosine Kinase Inhibitor Pretreated Mantle-Cell LymphomaMichael Wang, Nirav N. Shah, Nicole Lamanna et al.|Journal of Clinical Oncology|2023Cited by 106
A phase Ib/II study evaluating activity and tolerability of BTK inhibitor PCI-32765 and ofatumumab in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and related diseases.Samantha Jaglowski, John C. Byrd, Jeffrey A. Jones et al.|Journal of Clinical Oncology|2012Cited by 65
Tafasitamab and lenalidomide in large B-cell lymphoma: real-world outcomes in a multicenter retrospective studyDavid Qualls, Gilles Salles, Nicholas Lambert et al.|Blood|2023Cited by 47
Tafasitamab and Lenalidomide in Relapsed/Refractory Large B Cell Lymphoma (R/R LBCL): Real World Outcomes in a Multicenter Retrospective StudyDavid Qualls, Connie Lee Batlevi, Michael J. Buege et al.|Blood|2022Cited by 20
Pirtobrutinib, a highly selective, noncovalent (reversible) BTKi in R/R marginal zone lymphoma: phase 1/2 BRUIN studyKrish Patel, P. L. Zinzani, Julie M Vose et al.|Blood Advances|2026Cited by 1